An update on antidepressant use in bipolar depression

Current Psychiatry Reports

Volumn 14, Issue 6, 2012, Pages 696-704

  Sidor, Michelle M ^a   MacQueen, Glenda M ^b  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF CALGARY   (Canada)

Author keywords

Antidepressant; Bipolar depression; Bipolar disorder; Major depression; Pharmacotherapy; Prescribing guidelines; Psychiatry; Remission; Response; Switch; Treatment outcome

Indexed keywords

AMFEBUTAMONE; AMITRIPTYLINE; ANTIDEPRESSANT AGENT; CITALOPRAM; FLUOXETINE; LAMOTRIGINE; LITHIUM; MOOD STABILIZER; OLANZAPINE; PAROXETINE; PLACEBO; QUETIAPINE; SEROTONIN NORADRENALIN REUPTAKE INHIBITOR; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TRICYCLIC ANTIDEPRESSANT AGENT; VENLAFAXINE;

ARTICLE; BIPOLAR DEPRESSION; BIPOLAR I DISORDER; BIPOLAR II DISORDER; CLINICAL FEATURE; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG USE; HUMAN; META ANALYSIS (TOPIC); MOOD DISORDER; PRACTICE GUIDELINE; PREDICTION; RANDOMIZED CONTROLLED TRIAL (TOPIC); RAPID CYCLING BIPOLAR DISORDER; RISK BENEFIT ANALYSIS;

ANTIDEPRESSIVE AGENTS; ANTIPSYCHOTIC AGENTS; BIPOLAR DISORDER; HUMANS; PRACTICE GUIDELINES AS TOPIC; RISK; TREATMENT OUTCOME;

EID: 84870777990     PISSN: 15233812     EISSN: 15351645     Source Type: Journal    
DOI: 10.1007/s11920-012-0323-6     Document Type: Article

References (64)

1. Frye MA, Ha K, Kanba S, et al. International consensus group on depression prevention in bipolar disorder. J Clin Psychiatry. 2011;72(10):1295-310.
2. Judd LL, Akiskal HS. Depressive episodes and symptoms dominate the longitudinal course of bipolar disorder. Curr Psychiatry Rep. 2003;5(6):417-8. (Pubitemid 38899236)
3. Altshuler LL, Post RM, Black DO, et al. Subsyndromal depressive symptoms are associated with functional impairment in patients with bipolar disorder: results of a large, multisite study. J Clin Psychiatry. 2006;67(10):1551-60. (Pubitemid 44787437)
4. Ghaemi SN. Antidepressants in bipolar depression: the clinical debate. Aust N Z J Psychiatry. 2012;46(4):298-301.
5. Wehr TA, Goodwin FK. Rapid cycling in manic-depressives induced by tricyclic antidepressants. Arch Gen Psychiatry. 1979;36 (5):555-9. (Pubitemid 9201187)
6. Licht RW, Gijsman H, Nolen WA, Angst J. Are antidepressants safe in the treatment of bipolar depression? A critical evaluation of their potential risk to induce switch into mania or cycle acceleration. Acta Psychiatr Scand. 2008;118(5):337-46.
7. Gijsman HJ, Geddes JR, Rendell JM, Nolen WA, Goodwin GM. Antidepressants for bipolar depression: a systematic review of randomized, controlled trials. Am J Psychiatry. 2004;161(9):1537-47. (Pubitemid 39201448)
8. Sachs GS, Nierenberg AA, Calabrese JR, et al. Effectiveness of adjunctive antidepressant treatment for bipolar depression. N Engl J Med. 2007;356(17):1711-22. (Pubitemid 46658703)
9. McElroy SL, Weisler RH, Chang W, et al. A double-blind, placebo-controlled study of quetiapine and paroxetine as monotherapy in adults with bipolar depression (EMBOLDEN II). J Clin Psychiatry. 2010;71(2):163-74.
10. Sidor MM, Macqueen GM. Antidepressants for the acute treatment of bipolar depression: a systematic review and meta-analysis. J Clin Psychiatry. 2011;72(2):156-67.
11. Guyatt GH, Oxman AD, Kunz R, et al. What is "quality of evidence" and why is it important to clinicians? BMJ. 2008;336 (7651):995-8. (Pubitemid 351656090)
12. Greil W, Haberle A, Haueis P, Grohmann R, Russmann S. Pharmacotherapeutic trends in 2231 psychiatric inpatients with bipolar depression from the International AMSP Project between 1994 and 2009. J Affect Disord. 2012;136(3):534-42.
13. Baldessarini RJ, Leahy L, Arcona S, et al. Patterns of psychotropic drug prescription for U.S. patients with diagnoses of bipolar disorders. Psychiatr Serv. 2007;58(1):85-91.
14. Pacchiarotti I, Valenti M, Colom F, et al. Differential outcome of bipolar patients receiving antidepressant monotherapy versus combination with an antimanic drug. J Affect Disord. 2010.
15. Chiesa A, Chierzi F, De Ronchi D, Serretti A. Quetiapine for bipolar depression: a systematic review and meta-analysis. Int Clin Psychopharmacol. 2012;27(2):76-90.
16. Geddes JR, Calabrese JR, Goodwin GM. Lamotrigine for treatment of bipolar depression: independent meta-analysis and metaregression of individual patient data from five randomised trials. Br J Psychiatry. 2009;194(1):4-9.
17. Calabrese JR, Huffman RF, White RL, et al. Lamotrigine in the acute treatment of bipolar depression: results of five doubleblind, placebo-controlled clinical trials. Bipolar Disord. 2008;10 (2):323-33. (Pubitemid 351637697)
18. Sidor MM, MacQueen GM. Reply to: Antidepressants in acute bipolar-depression: an inconclusive meta-analysis. J Clin Psychiatry. 2011;72(3):415.
19. van der Loos ML, Mulder P, Hartong EG, et al. Efficacy and safety of two treatment algorithms in bipolar depression consisting of a combination of lithium, lamotrigine or placebo and paroxetine. Acta Psychiatr Scand. 2010;122(3):246-54.
20. van der Loos ML, Mulder PG, Hartong EG, et al. Efficacy and safety of lamotrigine as add-on treatment to lithium in bipolar depression: a multicenter, double-blind, placebo-controlled trial. J Clin Psychiatry. 2009;70(2):223-31.
21. Pilhatsch M, Wolf R, Winter C, Lewitzka U, Bauer M. Comparison of paroxetine and amitriptyline as adjunct to lithium maintenance therapy in bipolar depression: a reanalysis of a randomized, double-blind study. J Affect Disord. 2010;126(3):453-7.
22. Bauer M, Zaninelli R, Muller-Oerlinghausen B, Meister W. Paroxetine and amitriptyline augmentation of lithium in the treatment of major depression: a double-blind study. J Clin Psychopharmacol. 1999;19(2):164-71. (Pubitemid 29161962)
23. Li CT, Bai YM, Huang YL, et al. Association between antidepressant resistance in unipolar depression and subsequent bipolar disorder: cohort study. Br J Psychiatry. 2012;200(1):45-51.
24. Goodwin GM. Bipolar depression and treatment with antidepressants. Br J Psychiatry. 2012;200(1):5-6.
25. Tondo L, Vazquez G, Baldessarini RJ. Mania associated with antidepressant treatment: comprehensive meta-analytic review. Acta Psychiatr Scand. 2010;121(6):404-14.
26. Nemeroff CB, Evans DL, Gyulai L, et al. Double-blind, placebo-controlled comparison of imipramine and paroxetine in the treatment of bipolar depression. Am J Psychiatry. 2001;158(6):906-12. (Pubitemid 32547620)
27. Keck Jr PE, Corya SA, Altshuler LL, et al. Analyses of treatmentemergent mania with olanzapine/fluoxetine combination in the treatment of bipolar depression. J Clin Psychiatry. 2005;66(5):611-6. (Pubitemid 40733704)
28. Perlis RH, Ostacher MJ, Goldberg JF, et al. Transition to mania during treatment of bipolar depression. Neuropsychopharmacology. 2010;35(13):2545-52.
29. Undurraga J, Baldessarini RJ, Valenti M, et al. Bipolar depression: clinical correlates of receiving antidepressants. J Affect Disord. 2012;139(1):89-93.
30. Ghaemi SN, Wingo AP, Filkowski MA, Baldessarini RJ. Longterm antidepressant treatment in bipolar disorder: meta-analyses of benefits and risks. Acta Psychiatr Scand. 2008;118(5):347-56.
31. Ghaemi SN, Ostacher MM, El-Mallakh RS, et al. Antidepressant discontinuation in bipolar depression: a Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD) randomized clinical trial of long-term effectiveness and safety. J Clin Psychiatry. 2010;71(4):372-80.
32. Strejilevich SA, Martino DJ, Marengo E, et al. Long-term worsening of bipolar disorder related with frequency of antidepressant exposure. Ann Clin Psychiatry. 2011;23(3):186-92.
33. Post RM, Leverich GS, Altshuler LL, et al. Relationship of prior antidepressant exposure to long-term prospective outcome in bipolar I disorder outpatients. J Clin Psychiatry. 2012.
34. Post RM, Altshuler LL, Leverich GS, et al. Mood switch in bipolar depression: comparison of adjunctive venlafaxine, bupropion and sertraline. Br J Psychiatry. 2006;189:124-31. (Pubitemid 44231270)
35. Leverich GS, Altshuler LL, Frye MA, et al. Risk of switch in mood polarity to hypomania or mania in patients with bipolar depression during acute and continuation trials of venlafaxine, sertraline, and bupropion as adjuncts to mood stabilizers. Am J Psychiatry. 2006;163(2):232-9. (Pubitemid 44480842)
36. Bond DJ, Noronha MM, Kauer-Sant'Anna M, Lam RW, Yatham LN. Antidepressant-associated mood elevations in bipolar II disorder compared with bipolar I disorder and major depressive disorder: a systematic review and meta-analysis. J Clin Psychiatry. 2008;69(10):1589-601.
37. Swartz HA, Thase ME. Pharmacotherapy for the treatment of acute bipolar II depression: current evidence. J Clin Psychiatry. 2011;72 (3):356-66.
38. Amsterdam JD, Shults J. Comparison of fluoxetine, olanzapine, and combined fluoxetine plus olanzapine initial therapy of bipolar type I and type II major depression-lack of manic induction. J Affect Disord. 2005;87(1):121-30. (Pubitemid 40828211)
39. Amsterdam JD, Shults J, Brunswick DJ, Hundert M. Short-term fluoxetine monotherapy for bipolar type II or bipolar NOS major depression - low manic switch rate. Bipolar Disord. 2004;6(1):75-81. (Pubitemid 38256507)
40. Amsterdam JD, Shults J. Comparison of short-term venlafaxine versus lithium monotherapy for bipolar II major depressive episode: a randomized open-label study. J Clin Psychopharmacol. 2008;28(2):171-81. (Pubitemid 351417122)
41. Parker G, Tully L, Olley A, Hadzi-Pavlovic D. SSRIs as mood stabilizers for Bipolar II Disorder? A proof of concept study. J Affect Disord. 2006;92(2-3):205-14.
42. Amsterdam JD, Shults J. Efficacy and mood conversion rate of short-term fluoxetine monotherapy of bipolar II major depressive episode. J Clin Psychopharmacol. 2010;30(3):306-11.
43. Amsterdam JD, Shults J. Efficacy and safety of long-term fluoxetine versus lithium monotherapy of bipolar II disorder: a randomized, double-blind, placebo-substitution study. Am J Psychiatry. 2010;167(7):792-800.
44. Gao K, Kemp DE, Ganocy SJ, et al. Treatment-emergent mania/hypomania during antidepressant monotherapy in patients with rapid cycling bipolar disorder. Bipolar Disord. 2008;10(8):907-15.
45. Wehr TA, Sack DA, Rosenthal NE, Cowdry RW. Rapid cycling affective disorder: contributing factors and treatment responses in 51 patients. Am J Psychiatry. 1988;145(2):179-84. (Pubitemid 18058361)
46. Mendlewicz J, Massat I, Linotte S, et al. Identification of clinical factors associated with resistance to antidepressants in bipolar depression: results from an European Multicentre Study. Int Clin Psychopharmacol. 2010;25(5):297-301.
47. Valenti M, Pacchiarotti I, Bonnin CM, et al. Risk factors for antidepressant-related switch to mania. J Clin Psychiatry. 2012;73(2):e271-6.
48. Pacchiarotti I, Valenti M, Bonnin CM, et al. Factors associated with initial treatment response with antidepressants in bipolar disorder. Eur Neuropsychopharmacol. 2011;21(5):362-9.
49. Kemp DE, Ganocy SJ, Brecher M, et al. Clinical value of early partial symptomatic improvement in the prediction of response and remission during short-term treatment trials in 3369 subjects with bipolar I or II depression. J Affect Disord. 2011;130(1-2):171-9.
50. Li J, Kuk AY, Rush AJ. A practical approach to the early identification of antidepressant medication non-responders. Psychol Med. 2011;1-8.
51. Nakajima S, Uchida H, Suzuki T, et al. Is switching antidepressants following early nonresponse more beneficial in acutephase treatment of depression?: a randomized open-label trial. Prog Neuropsychopharmacol Biol Psychiatry. 2011;35(8): 1983-9.
52. Lin CH, Lane HY, Chen CC, Juo SH, Yen CF. Predictors of fluoxetine remission for hospitalized patients with major depressive disorder. Psychiatry Clin Neurosci. 2011;65(5):510-7.
53. Nierenberg AA, Farabaugh AH, Alpert JE, et al. Timing of onset of antidepressant response with fluoxetine treatment. Am J Psychiatry. 2000;157(9):1423-8.
54. Tohen M, Case M, Trivedi MH, et al. Olanzapine/fluoxetine combination in patients with treatment-resistant depression: rapid onset of therapeutic response and its predictive value for subsequent overall response in a pooled analysis of 5 studies. J Clin Psychiatry. 2010;71(4):451-62.
55. Szegedi A, Jansen WT, van Willigenburg AP, et al. Early improvement in the first 2 weeks as a predictor of treatment outcome in patients with major depressive disorder: a meta-analysis including 6562 patients. J Clin Psychiatry. 2009;70 (3):344-53.
56. Connolly KR, Thase ME. The clinical management of bipolar disorder: a review of evidence-based guidelines. Prim Care Companion CNS Disord. 2011;13(4).
57. NICE. NICE clinical guidelines. Bipolar disorder. The management of bipolar disorder in adults, children and adolescents, in primary and secondary care. National Institute for Health and Clinical Excellence, update 2009. 2009.
58. Goodwin GM. Evidence-based guidelines for treating bipolar disorder: revised second edition-recommendations from the British Association for Psychopharmacology. J Psychopharmacol. 2009;23(4):346-88.
59. Yatham LN, Kennedy SH, Schaffer A, et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) collaborative update of CANMAT guidelines for the management of patients with bipolar disorder: update 2009. Bipolar Disord. 2009;11(3):225-55.
60. American Psychiatric Association. Practice guideline for the treatment of patients with bipolar disorder (revision). Am J Psychiatry. 2002;159(4 Suppl):1-50.
61. Grunze H, Vieta E, Goodwin GM, et al. The World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for the Biological Treatment of Bipolar Disorders: Update 2010 on the treatment of acute bipolar depression. World J Biol Psychiatry. 2010;11(2):81-109.
62. Cohn JB, Collins G, Ashbrook E, Wernicke JF. A comparison of fluoxetine imipramine and placebo in patients with bipolar depressive disorder. Int Clin Psychopharmacol. 1989;4(4):313-22.
63. Shelton RC, Stahl SM. Risperidone and paroxetine given singly and in combination for bipolar depression. J Clin Psychiatry. 2004;65(12):1715-9.
64. Tohen M, Vieta E, Calabrese J, et al. Efficacy of olanzapine and olanzapine-fluoxetine combination in the treatment of bipolar I depression. Arch Gen Psychiatry. 2003;60(11):1079-88. (Pubitemid 37429647)